Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer

被引:23
|
作者
Sun, Xiaoxiang [1 ]
Tang, Huanyin [1 ]
Chen, Yu [1 ]
Chen, Zhixi [1 ]
Hu, Zhiyi [2 ]
Cui, Zhen [1 ]
Tao, Yaming [1 ]
Yuan, Jian [2 ]
Fu, Yun [2 ]
Zhuang, Zhigang [2 ]
He, Qizhi [2 ]
Li, Qian [2 ]
Xu, Xianghong [2 ]
Wan, Xiaoping [1 ,2 ]
Jiang, Ying [1 ,3 ]
Mao, Zhiyong [1 ,2 ,3 ,4 ]
机构
[1] Tongji Univ, Infant Hosp,Sch Life Sci & Technol, Clin & Translat Res Ctr Shanghai Matern & Infant H, Frontier Sci Ctr Stem Cell Res,Shanghai Key Lab Ma, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai Matern & Infant Hosp 1, Shanghai Key Lab Maternal Fetal Med, Sch Med, Shanghai, Peoples R China
[3] Tongji Univ, Sch Life Sci & Technol, Shanghai Key Lab Signaling & Dis Res, Shanghai, Peoples R China
[4] Tongji Univ, Tsingtao Adv Res Inst, Qingdao, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; REPAIR; PROTEIN; EXPRESSION; RESISTANCE; OLAPARIB; THERAPY; STRESS; LIGASE;
D O I
10.1038/s43018-023-00535-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sun et al. identify the deubiquitinase USP15 as a regulator of PARP1 stability in triple-negative breast cancer and show that the hormone receptors ER, PR and HER2 inhibit USP15-mediated PARP1 stabilization, modulating base excision repair. Poly(ADP-ribose) polymerase 1 (PARP1) is essential for the progression of several types of cancers. However, whether and how PARP1 is stabilized to promote genomic stability in triple-negative breast cancer (TNBC) remains unknown. Here, we demonstrated that the deubiquitinase USP15 interacts with and deubiquitinates PARP1 to promote its stability, thereby stimulating DNA repair, genomic stability and TNBC cell proliferation. Two PARP1 mutations found in individuals with breast cancer (E90K and S104R) enhanced the PARP1-USP15 interaction and suppressed PARP1 ubiquitination, thereby elevating the protein level of PARP1. Importantly, we found that estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) inhibited USP15-mediated PARP1 stabilization through different mechanisms. ER bound to the USP15 promoter to suppress its expression, PR suppressed the deubiquitinase activity of USP15, and HER2 abrogated the PARP1-USP15 interaction. The specific absence of these three receptors in TNBC results in high PARP1 levels, leading to increases in base excision repair and female TNBC cell survival.
引用
收藏
页码:716 / +
页数:35
相关论文
共 50 条
  • [1] Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer
    Xiaoxiang Sun
    Huanyin Tang
    Yu Chen
    Zhixi Chen
    Zhiyi Hu
    Zhen Cui
    Yaming Tao
    Jian Yuan
    Yun Fu
    Zhigang Zhuang
    Qizhi He
    Qian Li
    Xianghong Xu
    Xiaoping Wan
    Ying Jiang
    Zhiyong Mao
    Nature Cancer, 2023, 4 : 716 - 733
  • [2] MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer
    Radojicic, Jelena
    Zaravinos, Apostolos
    Vrekoussis, Thomas
    Kafousi, Maria
    Spandidos, Demetrios A.
    Stathopoulos, Efstathios N.
    CELL CYCLE, 2011, 10 (03) : 507 - 517
  • [3] Outcomes of ER, PR, HER2, and triple-negative mutated breast cancer with brain metastasis.
    O'Shea, Patrick Joseph
    Tatineni, Vineeth
    Rauf, Yasmeen
    Jia, Xuefei
    Murphy, Erin Sennett
    Chao, Samuel T.
    Suh, John H.
    Peereboom, David M.
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
    Perez, Edith A.
    Patel, Tejal
    Moreno-Aspitia, Alvaro
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (02) : 261 - 271
  • [5] Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
    Edith A. Perez
    Tejal Patel
    Alvaro Moreno-Aspitia
    Breast Cancer Research and Treatment, 2010, 121 : 261 - 271
  • [6] PARP1 in triple-negative breast cancer: Expression and therapeutic potential
    Cotter, M. B.
    Pierce, A.
    McGowan, P. M.
    Madden, S. F.
    Flanagan, L.
    Quinn, C.
    Evoy, D.
    Crown, J.
    McDermott, E.
    Duffy, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Her2 FISH amplification in ER/PR/Her2 IHC negative breast cancer
    Sahoo, Sunati
    Hwang, Helena
    CANCER RESEARCH, 2015, 75
  • [8] Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer
    Gong, Rong
    Ma, ZhongYe
    He, LinHao
    Jiang, ShiLong
    Cao, DongSheng
    Cheng, Yan
    CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 382
  • [9] Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer
    Liang, Hongyan
    Tan, Antoinette R.
    IDRUGS, 2010, 13 (09) : 646 - 656
  • [10] The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
    Luo, Jiayan
    Jin, Juan
    Yang, Fang
    Sun, Zijia
    Zhang, Wenwen
    Shi, Yaqin
    Xu, Jing
    Guan, Xiaoxiang
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2016, 12 (12): : 1500 - 1510